SCHEMBL2555591

SCHEMBL2555591

C[C@@]12CCC[C@H]1[C@@H]1CC[C@H]3CC(O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 1/20 1.00
CDK5 Q00535 1/20 0.70
CDK5R1 Q15078 1/20 0.70
LMNA P02545 3/20 0.67
GPBAR1 Q8TDU6 2/20 0.67
CYP3A4 P08684 2/20 0.67
SHBG P04278 1/20 0.67
SERPINA6 P08185 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2C9 P11712 1/20 0.67
TSHR P16473 1/20 0.67
CYP2C19 P33261 1/20 0.67
HSD17B10 Q99714 1/20 0.67
GRIN1 Q05586 2/20 0.63
GRIN2B Q13224 2/20 0.63
G6PD P11413 2/20 0.59
MEN1 O00255 1/20 0.59
GABRP O00591 1/20 0.59
GABRD O14764 1/20 0.59
GMNN O75496 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047682 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL15963473 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL3130550 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL3440809 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL13785427 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL11128263 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL21802632 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL20781172 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL20781187 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1
SCHEMBL11250886 1.00 NR1I3 (1.00) NR1I3CDK5CDK5R1LMNAGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4430057-A1 3.ALPHA.-SUBSTITUTED 3.BETA.-HYDROXY 17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABA-A RECEPTOR Umecrine AB (SE) 2024-09-18 EP claimed
WO-2023083978-A1 3.ALPHA.-SUBSTITUTED 3.BETA.-HYDROXY 17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABA-A RECEPTOR UMECRINE AB (SE) 2023-05-19 WO claimed
EP-1858522-A4 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS NASCENT PHARMACEUTICAL INC (US) 2008-07-16 EP claimed
EP-1858522-A1 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS Nascent Pharmaceutical, Inc. (US) 2007-11-28 EP claimed
WO-2006094026-A1 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS NASCENT PHARMACEUTICALS, INC. (US) 2006-09-08 WO claimed
US-3968132-A (17R)-Spiro-[androstane-17,1'-cyclobutan]-2'-ones, methods for their manufacture and intermediates useful therein SCHERING CORPORATION (US) 1976-07-06 US claimed
EP-4430057-A1 3.ALPHA.-SUBSTITUTED 3.BETA.-HYDROXY 17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABA-A RECEPTOR Umecrine AB (SE) 2024-09-18 EP disclosed
WO-2023083978-A1 3.ALPHA.-SUBSTITUTED 3.BETA.-HYDROXY 17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABA-A RECEPTOR UMECRINE AB (SE) 2023-05-19 WO disclosed
EP-3016660-A1 SHIP INHIBITION TO COMBAT OBESITY The Research Foundation for the State University of New York (US) 2016-05-11 EP disclosed
WO-2015003003-A1 SHIP INHIBITION TO COMBAT OBESITY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2015-01-08 WO disclosed
EP-2683730-A1 ANDROSTANEDIOL DERIVATIVES AS PLANT GROWTH REGULATOR COMPOUNDS Syngenta Participations AG (CH) 2014-01-15 EP disclosed
EP-2556055-A2 SHIP INHIBITORS AND USES THEREOF The Research Foundation of the State University of New York (US) 2013-02-13 EP disclosed
WO-2012123324-A1 ANDROSTANEDIOL DERIVATIVES AS PLANT GROWTH REGULATOR COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2012-09-20 WO disclosed
WO-2011127465-A2 SHIP INHIBITORS AND USES THEREOF THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 2011-10-13 WO disclosed
EP-1858522-A4 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS NASCENT PHARMACEUTICAL INC (US) 2008-07-16 EP disclosed
EP-1858522-A1 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS Nascent Pharmaceutical, Inc. (US) 2007-11-28 EP disclosed
EP-1858523-A1 COMBINAION THERAPY FOR TOPICAL APPLICATION IN THE TREATMENT OF DRY EYE SYNDROME Nascent Pharmaceutical, Inc. (US) 2007-11-28 EP disclosed
WO-2006094026-A1 PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS NASCENT PHARMACEUTICALS, INC. (US) 2006-09-08 WO disclosed
WO-2006094028-A1 COMBINAION THERAPY FOR TOPICAL APPLICATION IN THE TREATMENT OF DRY EYE SYNDROME NASCENT PHARMACEUTICALS, INC. (US) 2006-09-08 WO disclosed
WO-2004034029-A2 SCREENING SYSTEMS AND METHODS FOR IDENTIFYING MODULATORS OF XENOBIOTIC METABOLISM BAYLOR COLLEGE OF MEDICINE (US) 2004-04-22 WO disclosed